Teriparatide

At a glance

Overview

Teriparatide provides a pharmacologically active fragment of PTH through subcutaneous injection. US indications include high-risk postmenopausal osteoporosis, increasing bone mass in men with primary or hypogonadal osteoporosis at high risk, and glucocorticoid-associated osteoporosis in selected high-risk adults. Its therapeutic role is based on skeletal fragility and clinical evidence, rather than increasing muscle mass. The Forteo label and approved generic labels define the relevant populations and precautions. Teriparatide is different from full-length PTH replacement for hypoparathyroidism and from sustained-release palopegteriparatide. Reports of off-label fracture-healing use should be distinguished from the approved osteoporosis indications.

Supporting sources [1] [2]

How it works

Teriparatide binds PTH1 receptors on bone and kidney cells. Brief daily receptor stimulation favors osteoblast activity and new bone formation, while continuous excess PTH can increase bone resorption. Treatment changes calcium metabolism as well as bone remodeling, which explains calcium-related precautions. The first 34 residues retain the major receptor-activating activity of full-length PTH, but clinical effects depend on delivery pattern and the condition being treated.

Supporting sources [1] [2]

Which osteoporosis populations are covered?

The label covers postmenopausal women at high fracture risk, selected men with primary or hypogonadal osteoporosis, and adults with osteoporosis associated with sustained systemic glucocorticoid treatment. Prior treatment failure or intolerance also matters. The evidence claim in men centers on increased bone mass rather than identical fracture data across all populations.

Supporting sources [1]

Fracture outcomes and their limits

A pivotal randomized trial in postmenopausal women with prior vertebral fractures found fewer new vertebral and nonvertebral fragility fractures with teriparatide than placebo. Bone mineral density also increased. These findings support high-risk osteoporosis care; they do not directly establish benefit for athletic performance, routine soft-tissue injury, or normal age-related concerns.

Supporting sources [1] [2]

Important precautions

Hypercalcemia, transient postural hypotension, possible worsening of kidney stones, and digoxin interactions need attention. The label advises avoiding patients with conditions that increase baseline osteosarcoma risk, including skeletal radiation exposure and open growth plates. Rat findings prompted the precaution; human observational studies have not demonstrated an increased osteosarcoma rate.

Supporting sources [1]

Is treatment always limited to two years?

Current US labeling allows use beyond two years only when a patient remains at or has returned to high fracture risk. That qualified wording differs from a universal lifetime prohibition. Long-term management also considers how to preserve skeletal gains after an anabolic course, with decisions based on the individual’s fracture risk.

Supporting sources [1]